

# CITATION REPORT

List of articles citing

**Cost description of chemotherapy regimens for the treatment of metastatic pancreas cancer**

**DOI: 10.1007/s12032-016-0762-8**  
**Medical Oncology, 2016, 33, 48.**

**Source:** <https://exaly.com/paper-pdf/63965953/citation-report.pdf>

**Version:** 2024-04-09

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
18	Dilemma of first line regimens in metastatic pancreatic adenocarcinoma. <i>World Journal of Gastroenterology</i> , <b>2016</b> , 22, 10124-10130	5.6	19
17	Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma. <i>Molecular Therapy</i> , <b>2016</b> , 24, 1150-1158	11.7	79
16	Comparison of treatment patterns, resource utilization, and cost of care in patients with metastatic pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine or FOLFIRINOX. <i>Expert Review of Clinical Pharmacology</i> , <b>2017</b> , 10, 559-565	3.8	16
15	Current status on the place of FOLFIRINOX in metastatic pancreatic cancer and future directions. <i>Therapeutic Advances in Gastroenterology</i> , <b>2017</b> , 10, 631-645	4.7	26
14	Comparison of treatment patterns and economic outcomes among metastatic pancreatic cancer patients initiated on nab-paclitaxel plus gemcitabine versus FOLFIRINOX. <i>Expert Review of Clinical Pharmacology</i> , <b>2017</b> , 10, 1153-1160	3.8	23
13	A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis. <i>Therapeutic Advances in Medical Oncology</i> , <b>2017</b> , 9, 75-82	5.4	34
12	How to Reliably Assess Nodal Status in Distal Pancreatectomy for Adenocarcinoma. <i>Pancreas</i> , <b>2018</b> , 47, 308-313	2.6	7
11	Cost-effectiveness of Pembrolizumab in Second-line Advanced Bladder Cancer. <i>European Urology</i> , <b>2018</b> , 74, 57-62	10.2	33
10	Assessing the Financial Burden Associated With Treatment Options for Resectable Pancreatic Cancer. <i>Annals of Surgery</i> , <b>2018</b> , 267, 544-551	7.8	11
9	Do current approaches to assessing therapy related adverse events align with the needs of long-term cancer patients and survivors?. <i>Cardio-Oncology</i> , <b>2018</b> , 4, 5	2.8	1
8	Comparison of conventional versus liposomal irinotecan in combination with fluorouracil for advanced pancreatic cancer: a single-institution experience. <i>Medical Oncology</i> , <b>2019</b> , 36, 87	3.7	7
7	Cancer drug development: The missing links. <i>Experimental Biology and Medicine</i> , <b>2019</b> , 244, 663-689	3.7	33
6	Pancreatic cancer treatment costs, including patient liability, by phase of care and treatment modality, 2000-2013. <i>Medicine (United States)</i> , <b>2019</b> , 98, e18082	1.8	10
5	Cost-Effectiveness Analysis of Biomarker-Guided Treatment for Metastatic Gastric Cancer in the Second-Line Setting. <i>Journal of Oncology</i> , <b>2020</b> , 2020, 2198960	4.5	5
4	Real-World Assessment of Health Care Costs for Patients with Metastatic Pancreatic Cancer Following Initiation of First-Line Chemotherapy. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , <b>2020</b> , 26, 872-878	1.9	
3	First-line and second-line treatment of patients with metastatic pancreatic adenocarcinoma in routine clinical practice across Europe: a retrospective, observational chart review study. <i>ESMO Open</i> , <b>2020</b> , 5,	6	20
2	Can we downstage locally advanced pancreatic cancer to resectable? A phase I/II study of induction oxaliplatin and 5-FU chemoradiation. <i>Journal of Gastrointestinal Oncology</i> , <b>2018</b> , 9, 922-935	2.8	3

1	Cost-effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab-paclitaxel in borderline resectable/locally advanced pancreatic cancer patients.. <i>Cancer Reports</i> , <b>2022</b> , e1565	1.5	2
---	--	-----	---